Literature DB >> 19617468

What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?

Federico Pea1, Mario Furlanut, Pierluigi Viale.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19617468      PMCID： PMC2715631          DOI： 10.1128/AAC.00256-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

1.  Omeprazole significantly reduces posaconazole serum trough level.

Authors:  Jan-Willem C Alffenaar; Sander van Assen; Tjip S van der Werf; Jos G W Kosterink; Donald R A Uges
Journal:  Clin Infect Dis       Date:  2009-03-15       Impact factor: 9.079

Review 2.  Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.

Authors:  Jeannina Smith; David Andes
Journal:  Ther Drug Monit       Date:  2008-04       Impact factor: 3.681

3.  Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations.

Authors:  Farkad Ezzet; David Wexler; Rachel Courtney; Gopal Krishna; Josephine Lim; Mark Laughlin
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

Authors:  Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

5.  Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Authors:  Gopal Krishna; Allen Moton; Lei Ma; Matthew M Medlock; James McLeod
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

6.  Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

Authors:  Gopal Krishna; Malaz AbuTarif; Fengjuan Xuan; Monika Martinho; David Angulo; Oliver A Cornely
Journal:  Pharmacotherapy       Date:  2008-10       Impact factor: 4.705

7.  Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.

Authors:  Rachel Courtney; David Wexler; Elaine Radwanski; Josephine Lim; Mark Laughlin
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335
  7 in total
  2 in total

1.  Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations.

Authors:  Piergiorgio Cojutti; Anna Candoni; Erica Simeone; Loretta Franceschi; Renato Fanin; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

2.  Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations.

Authors:  Jeroen Walravens; Joachim Brouwers; Isabel Spriet; Jan Tack; Pieter Annaert; Patrick Augustijns
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.